PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
212.67%
Some net income increase while VET is negative at -82.11%. John Neff would see a short-term edge over the struggling competitor.
-0.49%
Negative yoy D&A while VET is 74.84%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
382.89%
Some yoy growth while VET is negative at -77.87%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
154.37%
Slight usage while VET is negative at -30.06%. John Neff would note competitor possibly capturing more free cash unless expansions are needed here.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
159.57%
Growth of 159.57% while VET is zero at 0.00%. Bruce Berkowitz would see a difference in minor WC usage that might affect short-term cash flow if large.
6.84%
Lower 'other non-cash' growth vs. VET's 866.19%, indicating steadier reported figures. David Dodd would confirm no missed necessary write-downs or gains.
48.38%
Some CFO growth while VET is negative at -0.66%. John Neff would note a short-term liquidity lead over the competitor.
-15.78%
Both yoy lines negative, with VET at -9.05%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
5.77%
Acquisition growth of 5.77% while VET is zero at 0.00%. Bruce Berkowitz sees a mild outflow that must deliver synergy to justify the difference.
224.47%
Purchases well above VET's 100.00%. Michael Burry would see major cash outflow into securities vs. competitor’s approach, risking near-term FCF.
15.78%
Liquidation growth of 15.78% while VET is zero at 0.00%. Bruce Berkowitz sees a mild difference in monetizing portfolio items that must be justified by market valuations.
-18.37%
We reduce yoy other investing while VET is 925.59%. Joel Greenblatt sees a near-term cash advantage unless competitor’s intangible or side bets produce strong returns.
0.47%
Lower net investing outflow yoy vs. VET's 84.99%, preserving short-term cash. David Dodd would confirm expansions remain sufficient.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative yoy issuance while VET is 11.33%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
100.00%
Buyback growth of 100.00% while VET is zero at 0.00%. Bruce Berkowitz sees a modest per-share advantage that might accumulate if the stock is below intrinsic value.